SCHEMBL680227

SCHEMBL680227

Nc1ccc(Oc2cc3cn[nH]c3cc2-c2cn[nH]c2)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
ROCK1 Q13464 2/20 0.46
ROCK2 O75116 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
RAB9A P51151 1/20 0.46
HIF1A Q16665 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PKM P14618 1/20 0.43
HTT P42858 1/20 0.43
TLR8 Q9NR97 1/20 0.42
TRPA1 O75762 3/20 0.41
FEN1 P39748 2/20 0.39
SCN9A Q15858 5/20 0.38
FYN P06241 1/20 0.37
SRC P12931 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679260 0.86 TLR8 (0.59) KDM4EMEN1MAPTKMT2AROCK1
SCHEMBL680323 0.85 TLR8 (0.44) KDM4EMEN1MAPTKMT2AROCK1
SCHEMBL680202 0.85 TLR8 (0.46) KDM4EMEN1MAPTKMT2AROCK1
SCHEMBL680251 0.84 FGFR1 (0.45) KDM4EMEN1MAPTKMT2AROCK1
SCHEMBL680692 0.83 TLR8 (0.41) KDM4EMEN1MAPTKMT2AROCK1
SCHEMBL680260 0.82 TLR8 (0.46) KDM4EMEN1MAPTKMT2AROCK1
SCHEMBL680039 0.78 PLK4 (0.55) ROCK1ROCK2TRPA1FEN1SCN9A
SCHEMBL2876364 0.77 ROCK1 (0.58) KDM4EMEN1MAPTKMT2AROCK1
SCHEMBL680953 0.77 ROCK2 (0.44) KDM4EMEN1MAPTKMT2AROCK1
SCHEMBL680325 0.77 KDM4E (0.38) KDM4EMEN1MAPTKMT2AROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC KDM4E 1545/4885MEN1 176/4885MAPT 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.